Completed Enrollment

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

J1S-MC-JV01 -

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer.

Trial Summary

Age Range
12 months - 29 years
Conditions the trial is for
Desmoplastic Small Round Cell Tumor
What the trial is testing?
Cyclophosphamide, Ramucirumab, Vinorelbine
Could I receive a Placebo?
No
Enrollment Goal
34
Trial Dates
Jan 22, 2020 - Apr 2024
How long will I be in the trial?
Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have relapsed, recurrent or refractory DSRCT

  • Participant must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of enrollment

  • Participant must have received at least one line of prior systemic treatment at the time of enrollment

  • Participant must have adequate organ function, including blood, blood clotting, liver, kidney, heart and blood pressure control

Participants Must Not:

  • Participant must not be a candidate for surgical tumor removal at the time of enrollment

  • Participant must not have already taken ramucirumab

  • Participant must not have previously progressed on the combined regimen of cyclophos/vinorelbine and must not have known allergies to any of the agents in the regimen

  • Participant must not be at risk for/have history of serious bleeding/blood clot events; heart problems; blood pressure crises/brain disease

  • Participant must not be at risk for/have history of stomach/liver problems; fistulas, ulcers, perforations, or abdominal abscesses; non-healing wounds or broken bones

  • Participant must not have urinary outflow obstruction, Grade 2 hematuria, or non-infectious cystitis at the time of enrollment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources